Skip to main content

Research Repository

See what's under the surface

Advanced Search

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients

Chen, Li-Chia; Chen, Teng-Chou; Huang, Yaw-Bin; Chang, Chao-Sung


Li-Chia Chen

Teng-Chou Chen

Yaw-Bin Huang

Chao-Sung Chang


Background The launch of imatinib has turned chronic myeloid leukaemia (CML) into a chronic illness due to the dramatic improvement in survival. Several recent studies have demonstrated that poor adherence to imatinib may hamper the therapeutic outcomes and result in increased medical expenditures, whilst research on exploring the reasons for non-adherence to imatinib is still limited. Objective This study aimed to explore the experience of patients as they journey through their CML treatments and associated imatinib utilisation in order to understand the perceptions, attitudes and concerns that may influence adherence to imatinib treatment. Setting This study was conducted at oncology outpatient clinics in a medical centre in southern Taiwan. Methods CML patients who regularly attended the oncology outpatient clinics to receive imatinib treatment from October 2011 to March 2012 were invited to participate in the study. Semi-structured face-to-face interviews were used to explore patients’ experiences and views of their treatment, their current CML status and CML-related health conditions, their concerns about imatinib treatment and imatinib-taking behaviours. Patient interviews were recorded, transcribed verbatim and thematically analysed using the constant comparison approach. Main outcome measure Themes related to patients’ views of the disease and health conditions, worries and concerns influencing imatinib utilisation behaviours are reported. Results Forty-two CML patients participated in the interviews. The emerging themes included: acceptance of current disease and health status, misconceptions about disease progression, factors associated with adherence to imatinib, concerns and management of adverse drug effects. Participants regarded CML as a chronic disease but had misconceptions about disease progression, therapeutic monitoring, resistance to imatinib and symptoms of side effects. Participants were generally adherent to imatinib and favoured long-term prescriptions to avoid regular outpatient visits for medication refills. Experiencing adverse effect was the main reason influencing adherence and led to polypharmacy. Most participants altered medicine-taking behaviours to maintain long-term use of imatinib. Conclusion Taiwanese CML patients are adherent to imatinib but report changing their medication-taking behaviour due to adverse drug effects and associated polypharmacy. Patients’ misconceptions of the disease and medication suggests that it is necessary to improve communication between patients and healthcare professionals. Routinely providing updated information as part of the patient counselling process should be considered as a means of improving this communication.

Journal Article Type Article
Publication Date Feb 1, 2014
Journal International Journal of Clinical Pharmacy
Electronic ISSN 2210-7703
Publisher Humana Press
Peer Reviewed Peer Reviewed
Volume 36
Issue 1
APA6 Citation Chen, L., Chen, T., Huang, Y., & Chang, C. (2014). Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. International Journal of Clinical Pharmacy, 36(1), doi:10.1007/s11096-013-9867-8
Publisher URL
Copyright Statement Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf


International_Journal_of_Clinical_Pharmacy.pdf (189 Kb)

Copyright Statement
Copyright information regarding this work can be found at the following address:

Downloadable Citations